View in EDS HTML Full Text PDF Full Text

Serum neurofilament light chain cut‐off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis.

Saved in:
Bibliographic Details
Title: Serum neurofilament light chain cut‐off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis.
Authors: Brousse, Mehdi (AUTHOR), Delaby, Constance (AUTHOR), De La Cruz, Elisa (AUTHOR), Kuhle, Jens (AUTHOR), Benkert, Pascal (AUTHOR), Mondesert, Etienne (AUTHOR), Ginestet, Nelly (AUTHOR), Hirtz, Christophe (AUTHOR), Camu, William (AUTHOR), Lehmann, Sylvain (AUTHOR), Esselin, Florence (AUTHOR)
Source: European Journal of Neurology. Jul2023, Vol. 30 Issue 7, p1919-1927. 9p.
Subjects: Amyotrophic lateral sclerosis, Motor neuron diseases, Cytoplasmic filaments, Monoclonal gammopathies, Neurological disorders, Prognosis
Geographic Terms: Montpellier (France)
Abstract: Background: The neurofilament light chain (NfL) assay is gradually becoming an essential diagnostic tool for the diagnosis of many neurological diseases including amyotrophic lateral sclerosis (ALS). Different methods for the determination of this biomarker in serum have been developed in recent years. Methods: We measured blood NfL in 429 patients referred to the tertiary ALS center of Montpellier, France using two different ultrasensitive methods (Ella™ and Simoa™) and we compared the clinical performances of these two approaches. We also converted NfL values into age and body mass index‐adjusted Z‐scores to assess cut‐off values of this biomarker in this clinical context. Results: We show comparable diagnostic and prognostic performance of Ella™ and Simoa™ technologies in ALS, with specificities and sensitivities exceeding 80% for both. We propose cut‐off values for serum NfL in this clinical context, thus enabling the routine clinical use of this biomarker. Conclusion: The use of NfL in routine clinical practice will help predict survival and improve diagnostic accuracy by distinguishing ALS from other neurological diseases and motor neuron disease mimics. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 164115463
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Serum neurofilament light chain cut‐off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Brousse%2C+Mehdi%22">Brousse, Mehdi</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Delaby%2C+Constance%22">Delaby, Constance</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22De La Cruz%2C+Elisa%22">De La Cruz, Elisa</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kuhle%2C+Jens%22">Kuhle, Jens</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Benkert%2C+Pascal%22">Benkert, Pascal</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mondesert%2C+Etienne%22">Mondesert, Etienne</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ginestet%2C+Nelly%22">Ginestet, Nelly</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hirtz%2C+Christophe%22">Hirtz, Christophe</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Camu%2C+William%22">Camu, William</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lehmann%2C+Sylvain%22">Lehmann, Sylvain</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Esselin%2C+Florence%22">Esselin, Florence</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Journal+of+Neurology%22">European Journal of Neurology</searchLink>. Jul2023, Vol. 30 Issue 7, p1919-1927. 9p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Amyotrophic+lateral+sclerosis%22">Amyotrophic lateral sclerosis</searchLink><br /><searchLink fieldCode="DE" term="%22Motor+neuron+diseases%22">Motor neuron diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Cytoplasmic+filaments%22">Cytoplasmic filaments</searchLink><br /><searchLink fieldCode="DE" term="%22Monoclonal+gammopathies%22">Monoclonal gammopathies</searchLink><br /><searchLink fieldCode="DE" term="%22Neurological+disorders%22">Neurological disorders</searchLink><br /><searchLink fieldCode="DE" term="%22Prognosis%22">Prognosis</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Montpellier+%28France%29%22">Montpellier (France)</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: The neurofilament light chain (NfL) assay is gradually becoming an essential diagnostic tool for the diagnosis of many neurological diseases including amyotrophic lateral sclerosis (ALS). Different methods for the determination of this biomarker in serum have been developed in recent years. Methods: We measured blood NfL in 429 patients referred to the tertiary ALS center of Montpellier, France using two different ultrasensitive methods (Ella™ and Simoa™) and we compared the clinical performances of these two approaches. We also converted NfL values into age and body mass index‐adjusted Z‐scores to assess cut‐off values of this biomarker in this clinical context. Results: We show comparable diagnostic and prognostic performance of Ella™ and Simoa™ technologies in ALS, with specificities and sensitivities exceeding 80% for both. We propose cut‐off values for serum NfL in this clinical context, thus enabling the routine clinical use of this biomarker. Conclusion: The use of NfL in routine clinical practice will help predict survival and improve diagnostic accuracy by distinguishing ALS from other neurological diseases and motor neuron disease mimics. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=164115463
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/ene.15813
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 1919
    Subjects:
      – SubjectFull: Amyotrophic lateral sclerosis
        Type: general
      – SubjectFull: Motor neuron diseases
        Type: general
      – SubjectFull: Cytoplasmic filaments
        Type: general
      – SubjectFull: Monoclonal gammopathies
        Type: general
      – SubjectFull: Neurological disorders
        Type: general
      – SubjectFull: Prognosis
        Type: general
      – SubjectFull: Montpellier (France)
        Type: general
    Titles:
      – TitleFull: Serum neurofilament light chain cut‐off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Brousse, Mehdi
      – PersonEntity:
          Name:
            NameFull: Delaby, Constance
      – PersonEntity:
          Name:
            NameFull: De La Cruz, Elisa
      – PersonEntity:
          Name:
            NameFull: Kuhle, Jens
      – PersonEntity:
          Name:
            NameFull: Benkert, Pascal
      – PersonEntity:
          Name:
            NameFull: Mondesert, Etienne
      – PersonEntity:
          Name:
            NameFull: Ginestet, Nelly
      – PersonEntity:
          Name:
            NameFull: Hirtz, Christophe
      – PersonEntity:
          Name:
            NameFull: Camu, William
      – PersonEntity:
          Name:
            NameFull: Lehmann, Sylvain
      – PersonEntity:
          Name:
            NameFull: Esselin, Florence
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: Jul2023
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 13515101
          Numbering:
            – Type: volume
              Value: 30
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: European Journal of Neurology
              Type: main
ResultId 1